IQVIA Holdings (NYSE:IQV) Full Year 2024 Results
Key Financial Results
- Revenue: US$15.4b (up 2.8% from FY 2023).
- Net income: US$1.37b (up 1.1% from FY 2023).
- Profit margin: 8.9% (down from 9.1% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: US$7.57 (up from US$7.39 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
IQVIA Holdings EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.0%.
The primary driver behind last 12 months revenue was the Research & Development Solutions segment contributing a total revenue of US$8.53b (55% of total revenue). Notably, cost of sales worth US$10.0b amounted to 65% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$1.98b (50% of total expenses). Explore how IQV's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 7.1% from a week ago.
Valuation
It's possible that IQVIA Holdings could be undervalued with our 6-factor valuation analysis indicating a potential opportunity. To explore our complete evaluation click here and get an understanding of what analysts are thinking about the company's future.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:IQV
IQVIA Holdings
Provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Very undervalued with acceptable track record.
Similar Companies
Market Insights
Community Narratives


